This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
stem cell | 1702 |
cell transplantation | 1185 |
bone marrow | 956 |
hematopoietic stem | 720 |
median age | 663 |
peripheral blood | 650 |
mg kg | 650 |
barr virus | 608 |
overall survival | 580 |
patients received | 536 |
one patient | 486 |
conditioning regimen | 467 |
cd cells | 466 |
chronic gvhd | 456 |
cd cd | 439 |
acute gvhd | 431 |
host disease | 417 |
multiple sclerosis | 411 |
flow cytometry | 391 |
nk cells | 371 |
stem cells | 369 |
median follow | 369 |
median time | 360 |
mg dl | 349 |
allogeneic hematopoietic | 338 |
free survival | 322 |
design method | 318 |
high risk | 310 |
gvhd prophylaxis | 299 |
risk factors | 297 |
two patients | 282 |
years old | 271 |
immune response | 270 |
significantly higher | 270 |
case report | 269 |
cell lines | 265 |
pediatric patients | 261 |
united states | 251 |
immune system | 249 |
statistically significant | 246 |
viral infections | 238 |
cord blood | 228 |
complete remission | 228 |
allogeneic hsct | 223 |
unrelated donor | 220 |
transplant recipients | 219 |
graft failure | 213 |
primary immunodeficiency | 211 |
ng ml | 210 |
allogeneic stem | 209 |
cell transplant | 203 |
lymph node | 203 |
control group | 201 |
cmv reactivation | 197 |
myeloid leukemia | 195 |
graft versus | 195 |
cell lymphoma | 195 |
cumulative incidence | 194 |
introduction background | 193 |
three patients | 193 |
multiple myeloma | 191 |
mean age | 189 |
tumor cells | 187 |
acute myeloid | 185 |
increased risk | 184 |
gene expression | 182 |
nk cell | 181 |
versus host | 180 |
significant difference | 177 |
patients receiving | 175 |
myeloablative conditioning | 174 |
lymph nodes | 169 |
four patients | 169 |
kg day | 167 |
cell proliferation | 167 |
old male | 164 |
ebv infection | 164 |
cd cell | 163 |
retrospective study | 162 |
immune responses | 161 |
blood stem | 161 |
hodgkin lymphoma | 161 |
breast cancer | 160 |
patients undergoing | 160 |
exome sequencing | 158 |
dendritic cells | 156 |
donor chimerism | 155 |
multivariate analysis | 155 |
immune deficiency | 153 |
lymphoblastic leukemia | 153 |
grade ii | 153 |
acute lymphoblastic | 152 |
autologous stem | 152 |
two groups | 152 |
risk factor | 151 |
class i | 151 |
patients treated | 150 |
hematopoietic cell | 150 |
related mortality | 149 |
states background | 148 |
matched unrelated | 148 |
university hospital | 147 |
cd ra | 146 |
adult patients | 145 |
conditioning regimens | 144 |
side effects | 143 |
patients developed | 141 |
grade iii | 140 |
significant differences | 140 |
old female | 139 |
epithelial cells | 137 |
immune reconstitution | 137 |
sickle cell | 137 |
reduced intensity | 137 |
virus infection | 134 |
intensity conditioning | 134 |
combined immunodeficiency | 134 |
five patients | 134 |
hemophagocytic lymphohistiocytosis | 133 |
report text | 132 |
abstract case | 132 |
marrow transplantation | 131 |
year old | 130 |
infected cells | 130 |
adverse events | 130 |
patients without | 127 |
pg ml | 127 |
months post | 127 |
cell line | 126 |
high dose | 126 |
cell activation | 126 |
protein expression | 126 |
mononuclear cells | 125 |
ex vivo | 125 |
important role | 124 |
cell receptor | 123 |
cell source | 122 |
acute leukemia | 122 |
relapse mortality | 121 |
cmv infection | 121 |
healthy controls | 121 |
year os | 121 |
unrelated donors | 119 |
immune dysregulation | 119 |
chart review | 119 |
significantly lower | 116 |
neutrophil engraftment | 116 |
cell responses | 115 |
present study | 115 |
differential diagnosis | 115 |
cell carcinoma | 115 |
patients died | 113 |
genetic testing | 113 |
infectious complications | 113 |
nervous system | 112 |
platelet engraftment | 112 |
performed using | 112 |
respiratory tract | 111 |
cell disease | 110 |
recurrent infections | 110 |
abdominal pain | 109 |
viral load | 109 |
whole exome | 109 |
disease progression | 108 |
medical center | 107 |
results suggest | 107 |
acute graft | 107 |
renal function | 105 |
healthy donors | 105 |
replacement therapy | 105 |
cell count | 105 |
disease status | 104 |
central nervous | 104 |
matched sibling | 103 |
viral infection | 102 |
lung disease | 100 |
patient developed | 100 |
year overall | 99 |
median number | 99 |
data suggest | 97 |
clinical features | 97 |
cell subsets | 97 |
monoclonal antibodies | 97 |
blood cell | 96 |
clinical trials | 96 |
well tolerated | 96 |
single center | 96 |
one year | 96 |
autosomal recessive | 96 |
age years | 96 |
hematological malignancies | 95 |
patients underwent | 95 |
previously reported | 95 |
significantly increased | 95 |
least one | 95 |
mycophenolate mofetil | 95 |
days post | 94 |
significantly associated | 93 |
blood samples | 93 |
high levels | 93 |
bacterial infections | 93 |
univariate analysis | 92 |
long term | 92 |
matched related | 92 |
endothelial cells | 92 |
cell dose | 92 |
specific cd | 91 |
clinical trial | 91 |
six patients | 91 |
nkt cells | 91 |
retrospective chart | 91 |
retrospectively analyzed | 90 |
hsct recipients | 90 |
cell counts | 90 |
copies ml | 89 |
sibling donor | 89 |
consecutive patients | 88 |
aplastic anemia | 88 |
monoclonal antibody | 88 |
infectious diseases | 88 |
seven patients | 88 |
platelet count | 88 |
cell therapy | 88 |
cell surface | 88 |
mhc class | 87 |
retrospective analysis | 87 |
family history | 87 |
infectious mononucleosis | 87 |
statistical analysis | 86 |
cell death | 86 |
prospective study | 85 |
red blood | 85 |
herpes simplex | 84 |
marrow failure | 84 |
patients aged | 84 |
autoimmune diseases | 84 |
transcription factor | 84 |
haploidentical donor | 83 |
clinical presentation | 83 |
patient died | 83 |
first year | 83 |
natural killer | 83 |
patients transplanted | 82 |
cytokine production | 82 |
newly diagnosed | 82 |
time points | 82 |
cell lymphopenia | 81 |
whole blood | 81 |
severe combined | 81 |
dose chemotherapy | 81 |
complete response | 81 |
western blot | 81 |
statistical significance | 81 |
median duration | 80 |
hemophagocytic syndrome | 80 |
aml patients | 80 |
medical records | 80 |
cell development | 80 |
may also | 80 |
time pcr | 80 |
progressive disease | 79 |
mast cells | 79 |
blood cells | 78 |
cells ul | 78 |
eight patients | 78 |
cells kg | 78 |
transplant patients | 78 |
partial response | 78 |
plasma cells | 77 |
patients showed | 77 |
myelodysplastic syndrome | 76 |
significantly reduced | 76 |
renal failure | 76 |
fungal infections | 76 |
induction therapy | 76 |
copy number | 76 |
marrow transplant | 76 |
grade i | 76 |
intensive care | 75 |
renal transplant | 75 |
poor prognosis | 75 |
mixed chimerism | 74 |
nine patients | 74 |
clinical course | 74 |
two cases | 74 |
response rate | 74 |
generation sequencing | 74 |
severe acute | 74 |
immune suppression | 74 |
old woman | 74 |
cd count | 73 |
inkt cells | 73 |
residual disease | 73 |
analysis showed | 73 |
solid organ | 73 |
ct scan | 73 |
post transplant | 73 |
hematologic malignancies | 73 |
human herpesvirus | 73 |
common variable | 73 |
high grade | 73 |
positive cells | 73 |
chronic graft | 72 |
clinical manifestations | 72 |
th cells | 72 |
soft tissue | 72 |
squamous cell | 72 |
mm patients | 72 |
body weight | 72 |
among patients | 71 |
cell function | 71 |
related donor | 71 |
nasopharyngeal carcinoma | 71 |
patients presented | 71 |
determine whether | 71 |
human immunodeficiency | 71 |
turkey objective | 71 |
cell depletion | 71 |
median cd | 71 |
innate immune | 71 |
urinary tract | 70 |
kidney injury | 70 |
acute respiratory | 69 |
granulomatous disease | 69 |
survival rate | 69 |
primary immune | 69 |
informed consent | 69 |
based conditioning | 68 |
significant increase | 68 |
patient received | 68 |
ebv reactivation | 68 |
transplant cyclophosphamide | 68 |
mortality rate | 68 |
cvid patients | 67 |
immunodeficiency virus | 67 |
immune cells | 67 |
situ hybridization | 67 |
immunosuppressive therapy | 67 |
cd expression | 67 |
cell cycle | 67 |
patients diagnosed | 67 |
graft rejection | 67 |
kidney disease | 67 |
nephrotic syndrome | 67 |
last follow | 66 |
active disease | 66 |
first days | 66 |
higher risk | 66 |
inflammatory bowel | 66 |
full donor | 65 |
treatment option | 65 |
hiv infection | 65 |
chain reaction | 65 |
lymphocyte subsets | 65 |
immunoglobulin replacement | 65 |
transplanted patients | 65 |
significantly different | 65 |
assay system | 65 |
gene therapy | 64 |
previous studies | 64 |
disease free | 64 |
umbilical cord | 64 |
variable immunodeficiency | 64 |
organ transplantation | 64 |
one case | 64 |
donor lymphocyte | 64 |
survival rates | 64 |
primary immunodeficiencies | 64 |
relapsed refractory | 64 |
first time | 64 |
pediatric oncology | 63 |
declare background | 63 |
type i | 63 |
growth factor | 63 |
hemolytic anemia | 63 |
disease relapse | 63 |
lung cancer | 63 |
amino acid | 63 |
polymerase chain | 63 |
tyrosine kinase | 63 |
previously described | 63 |
respiratory infections | 63 |
allogeneic hct | 63 |
simplex virus | 62 |
bowel disease | 62 |
serum levels | 62 |
underwent hsct | 62 |
donor type | 62 |
analysis revealed | 62 |
clinical data | 61 |
cells showed | 61 |
blood cultures | 61 |
study period | 61 |
transplant related | 61 |
weight loss | 61 |
blood mononuclear | 61 |
patients achieved | 61 |
lymphoproliferative disease | 61 |
otitis media | 61 |
young adults | 61 |
line therapy | 61 |
old man | 60 |
relapse rate | 60 |
gastrointestinal tract | 60 |
autologous hsct | 60 |
cell lymphomas | 60 |
old boy | 60 |
iv acute | 60 |
total body | 59 |
old girl | 59 |
body irradiation | 59 |
wild type | 59 |
patient presented | 59 |
deficient mice | 59 |
cell depleted | 59 |
prospective studies | 59 |
immunocompromised patients | 59 |
included patients | 59 |
fungal infection | 59 |
chronic granulomatous | 59 |
bk virus | 59 |
newborn screening | 58 |
cells expressing | 58 |
logistic regression | 58 |
presenting cells | 58 |
compound heterozygous | 58 |
hsct patients | 58 |
solid tumors | 58 |
case series | 58 |
marrow biopsy | 58 |
inflammatory response | 58 |
tract infections | 58 |
signaling pathway | 58 |
renal transplantation | 57 |
next generation | 57 |
curative treatment | 57 |
months later | 57 |
care unit | 57 |
may lead | 56 |
died due | 56 |
ml min | 56 |
autosomal dominant | 56 |
diffuse large | 56 |
autologous hematopoietic | 56 |
specific antibodies | 56 |
risk patients | 56 |
expression levels | 56 |
related complications | 55 |
colorectal cancer | 55 |
signaling pathways | 55 |
salvage therapy | 55 |
specific antibody | 55 |
clinical symptoms | 55 |
respiratory failure | 55 |
haematopoietic stem | 55 |
antibody deficiency | 55 |
acute kidney | 55 |
cell differentiation | 55 |
pts received | 55 |
prognostic factors | 54 |
infectious disease | 54 |
lymphoproliferative disorders | 54 |
partial remission | 54 |
invasive fungal | 54 |
normal range | 54 |
higher incidence | 54 |
cell response | 54 |
pid patients | 54 |
patient population | 54 |
extremely rare | 54 |
two years | 54 |
underwent allogeneic | 54 |
risk group | 54 |
opportunistic infections | 53 |
gvhd grade | 53 |
doc id | 53 |
inclusion criteria | 53 |
serum creatinine | 53 |
viral dna | 53 |
may contribute | 53 |
antithymocyte globulin | 53 |
physical examination | 53 |
blood pressure | 53 |
cord uid | 53 |
examination revealed | 53 |
intravenous immunoglobulin | 53 |
underlying disease | 53 |
clinical outcomes | 53 |
day post | 53 |
post hsct | 53 |
identical sibling | 53 |
hemorrhagic cystitis | 53 |
organ transplant | 53 |
minimal residual | 52 |
results indicate | 52 |
also found | 52 |
diagnostic criteria | 52 |
vod sos | 52 |
atopic dermatitis | 52 |
treatment options | 52 |
supportive care | 52 |
first case | 52 |
lymphoproliferative disorder | 52 |
haploidentical hsct | 52 |
may help | 52 |
renal biopsy | 52 |
within months | 51 |
patients experienced | 51 |
plasma membrane | 51 |
inflammatory cytokines | 51 |
class ii | 51 |
pediatric hematology | 51 |
tract infection | 51 |
high incidence | 51 |
family members | 51 |
lupus erythematosus | 51 |
study group | 51 |
adverse effects | 51 |
early diagnosis | 51 |
male patients | 51 |
first line | 51 |
developed acute | 51 |
cell numbers | 51 |
ten patients | 51 |
retrospectively reviewed | 50 |
significantly decreased | 50 |
significant reduction | 50 |
associated hemophagocytic | 50 |
mouse model | 50 |
graft function | 50 |
prophylaxis consisted | 50 |
national institute | 50 |
cell types | 50 |
antibody response | 50 |
renal disease | 50 |
dependent manner | 50 |
vg vd | 50 |
analyzed using | 50 |
also observed | 50 |
low dose | 50 |
severe infections | 50 |
medical history | 50 |
cmv disease | 50 |
mg day | 49 |
two weeks | 49 |
findings suggest | 49 |
ebv dna | 49 |
undergoing hsct | 49 |
successfully treated | 49 |
within days | 49 |
allogeneic sct | 49 |
study included | 49 |
signal transduction | 49 |
respiratory distress | 49 |
results showed | 49 |
clinical practice | 49 |
phase i | 49 |
three cases | 48 |
cd positive | 48 |
primary infection | 48 |
igg levels | 48 |
autoimmune disease | 48 |
cell populations | 48 |
virus replication | 48 |
disease control | 48 |
recent studies | 48 |
healthy individuals | 48 |
breast carcinoma | 48 |
sos vod | 48 |
haploidentical donors | 48 |
haploidentical transplantation | 48 |
cell population | 48 |
childhood cancer | 48 |
cd ro | 48 |
term follow | 48 |
adaptive immune | 48 |
occlusive disease | 48 |
systemic lupus | 47 |
cohort study | 47 |
retrospective review | 47 |
relapse incidence | 47 |
respiratory syndrome | 47 |
cancer patients | 47 |
per day | 47 |
allogeneic transplantation | 47 |
zoster virus | 47 |
general population | 47 |
case reports | 47 |
myeloma patients | 47 |
white blood | 46 |
viral reactivation | 46 |
older patients | 46 |
undergoing allogeneic | 46 |
lymphoma patients | 46 |
iron overload | 46 |
antigen presentation | 46 |
th percentile | 46 |
underwent allo | 46 |
induction chemotherapy | 46 |
clinical characteristics | 46 |
progression free | 46 |
amino acids | 46 |
lower respiratory | 46 |
iu ml | 46 |
results demonstrate | 46 |
last years | 45 |
uric acid | 45 |
patients engrafted | 45 |
patient underwent | 45 |
cytokine release | 45 |
neutrophil count | 45 |
stimulating factor | 45 |
text introduction | 45 |
surface expression | 45 |
cell reconstitution | 44 |
higher levels | 44 |
skin lesions | 44 |
cancer cells | 44 |
increased susceptibility | 44 |
case presentation | 44 |
flow cytometric | 44 |
prognostic factor | 44 |
results show | 44 |
line treatment | 44 |
septic shock | 44 |
developed grade | 44 |
histological examination | 44 |
data indicate | 44 |
year survival | 44 |
antigen presenting | 44 |
immune cell | 44 |
reaction norm | 44 |
median day | 44 |
mechanical ventilation | 44 |
quantitative pcr | 44 |
immunoglobulin levels | 44 |
low levels | 44 |
preliminary results | 44 |
hla class | 43 |
may play | 43 |
increased expression | 43 |
severe chronic | 43 |
effective treatment | 43 |
hla matched | 43 |
biopsy showed | 43 |
molecular mechanisms | 43 |
median os | 43 |
mrna expression | 43 |
related donors | 43 |
stage iii | 43 |
treatment related | 43 |
antibody titers | 43 |
regression analysis | 43 |
iv agvhd | 43 |
secondary graft | 43 |
malignant disease | 43 |
year period | 42 |
year post | 42 |
diabetes mellitus | 42 |
clinically significant | 42 |
thymocyte globulin | 42 |
median days | 42 |
icu admission | 42 |
membrane protein | 42 |
low grade | 42 |
viral replication | 42 |
tumor cell | 42 |
varicella zoster | 42 |
platelet recovery | 42 |
maintenance therapy | 42 |
liver disease | 42 |
two different | 42 |
graft source | 42 |
remaining patients | 42 |
sinopulmonary infections | 42 |
weight gain | 42 |
progenitor cells | 42 |
influenza virus | 42 |
upper respiratory | 42 |
major cause | 42 |
per patient | 42 |
prostate cancer | 41 |
clinical outcome | 41 |
positive patients | 41 |
genetic correlations | 41 |
pulmonary function | 41 |
gene transfer | 41 |
calcineurin inhibitors | 41 |
missense mutation | 41 |
antifungal prophylaxis | 41 |
refractory disease | 41 |
oncology patients | 41 |
patient characteristics | 41 |
innate immunity | 41 |
chronic kidney | 41 |
pediatric population | 41 |
significantly better | 41 |
late effects | 41 |
examination showed | 41 |
i molecules | 41 |
burkitt lymphoma | 40 |
stage i | 40 |
patients suffering | 40 |
health care | 40 |
significant correlation | 40 |
febrile neutropenia | 40 |
fludarabine mg | 40 |
pet ct | 40 |
target cells | 40 |
organ failure | 40 |
liver biopsy | 40 |
factors associated | 40 |
received myeloablative | 40 |
matched donor | 40 |
antiviral therapy | 40 |
hepatocellular carcinoma | 40 |
protein levels | 40 |
recent years | 40 |
study aimed | 40 |
bacterial infection | 40 |
clinical phenotype | 40 |
gene mutation | 40 |
significant impact | 40 |
center experience | 40 |
one month | 39 |
low cd | 39 |
magnetic resonance | 39 |
extensive chronic | 39 |
overall response | 39 |
significant association | 39 |
tumor growth | 39 |
hearing loss | 39 |
macrophage activation | 39 |
developed chronic | 39 |
scid patients | 39 |
positive correlation | 39 |
cmv viremia | 39 |
cell culture | 39 |
developed severe | 39 |
lymphocyte count | 39 |
tumor necrosis | 39 |
widely used | 39 |
extracorporeal photopheresis | 39 |
per year | 39 |
recurrent respiratory | 39 |
cd kg | 39 |
critical role | 39 |
necrosis factor | 39 |
hematology oncology | 39 |
treatment group | 39 |
mast cell | 39 |
sanger sequencing | 39 |
clinical improvement | 38 |
stable disease | 38 |
primary graft | 38 |
group compared | 38 |
cell type | 38 |
aged years | 38 |
high level | 38 |
liver transplantation | 38 |
serum igg | 38 |
average age | 38 |
haploidentical transplant | 38 |
animal models | 38 |
inflammatory disease | 38 |
spinal cord | 38 |
confidence interval | 38 |
sibling donors | 38 |
infected patients | 38 |
mismatched unrelated | 38 |
ms risk | 38 |
grade iv | 38 |
three months | 38 |
significant decrease | 38 |
patients relapsed | 38 |
critically ill | 38 |
surgical resection | 38 |
clinical response | 38 |
liver transplant | 38 |
patients required | 38 |
leading cause | 38 |
ms patients | 38 |
treated patients | 38 |
mesenchymal stem | 38 |
immunohistochemical staining | 37 |
lymphocyte infusion | 37 |
six months | 37 |
radiation therapy | 37 |
transplant recipient | 37 |
taken together | 37 |
deficient patients | 37 |
elderly patients | 37 |
main cause | 37 |
years post | 37 |
effector cells | 37 |
smooth muscle | 37 |
patients compared | 37 |
term survival | 37 |
protective effect | 37 |
study showed | 37 |
agvhd grade | 37 |
specific ctls | 36 |
among children | 36 |
high mortality | 36 |
young children | 36 |
cell mobilization | 36 |
curative option | 36 |
neutrophil recovery | 36 |
may provide | 36 |
crucial role | 36 |
light chain | 36 |
within hours | 36 |
severe cgvhd | 36 |
renal cell | 36 |
immunosuppressive treatment | 36 |
high rate | 36 |
received hsct | 36 |
combined immune | 36 |
data show | 36 |
three groups | 36 |
national institutes | 36 |
dock deficiency | 36 |
dna repair | 36 |
virus type | 35 |
retrospective cohort | 35 |
one patients | 35 |
autoimmune cytopenias | 35 |
yellow fever | 35 |
thalassemia major | 35 |
pediatric cancer | 35 |
il rg | 35 |
real time | 35 |
haploidentical stem | 35 |
epithelial cell | 35 |
biopsy revealed | 35 |
interstitial lung | 35 |
absolute neutrophil | 35 |
submission id | 35 |
also known | 35 |
one hundred | 35 |
herpes virus | 35 |
genetic analysis | 35 |
cox regression | 35 |
transplant lymphoproliferative | 35 |
family donor | 35 |
platelet counts | 35 |
aldrich syndrome | 35 |
first months | 35 |
melphalan mg | 35 |
patients may | 35 |
electron microscopy | 35 |
commonly used | 35 |
potential therapeutic | 35 |
disclosure background | 35 |
consecutive days | 35 |
sequencing revealed | 35 |
serum samples | 35 |
dendritic cell | 35 |
cell viability | 35 |
first month | 34 |
initial presentation | 34 |
two months | 34 |
function mutations | 34 |
ewing sarcoma | 34 |
clinical immunology | 34 |
stromal cells | 34 |
broad spectrum | 34 |
kg cd | 34 |
female patients | 34 |
lymphocyte infusions | 34 |
trend towards | 34 |
united kingdom | 34 |
igg level | 34 |
ebv replication | 34 |
heterozygous mutation | 34 |
adoptive transfer | 34 |
current study | 34 |
total number | 34 |
nd allo | 34 |
cells infused | 34 |
elevated serum | 34 |
oxidative stress | 34 |
preliminary data | 34 |
measured using | 34 |
recurrent sinopulmonary | 34 |
safety profile | 34 |
heterozygous mutations | 34 |
biological activity | 34 |
older age | 34 |
immune deficiencies | 34 |
achieved cr | 34 |
transcription factors | 34 |
successful treatment | 34 |
patient age | 33 |
i ii | 33 |
different time | 33 |
median dose | 33 |
cells mm | 33 |
lymphocyte counts | 33 |
liver enzymes | 33 |
text background | 33 |
following hsct | 33 |
study population | 33 |
latent membrane | 33 |
human monoclonal | 33 |
potentially curative | 33 |
antibiotic therapy | 33 |
rare disease | 33 |
cgd patients | 33 |
pathogenic variant | 33 |
resonance imaging | 33 |
cgvhd patients | 33 |
well known | 33 |
host immune | 33 |
leukemia patients | 33 |
even though | 33 |
healthy control | 33 |
may occur | 33 |
plasma levels | 33 |
renal allograft | 33 |
medical university | 33 |
atg group | 33 |
autoimmune hemolytic | 33 |
significantly improved | 33 |
transplant outcomes | 33 |
computed tomography | 33 |
significant risk | 33 |
liver failure | 33 |
group patients | 33 |
younger patients | 33 |
effector memory | 33 |
underwent asct | 33 |
cancer cell | 33 |
clinical diagnosis | 33 |
term outcome | 32 |
regimen consisted | 32 |
low risk | 32 |
lymphocyte proliferation | 32 |
achieved complete | 32 |
nuclear antigen | 32 |
one week | 32 |
thrombotic microangiopathy | 32 |
adipose tissue | 32 |
genomic dna | 32 |
autologous sct | 32 |
virus infections | 32 |
age group | 32 |
studies showed | 32 |
previously healthy | 32 |
key role | 32 |
poor outcome | 32 |
factor viii | 32 |
therapeutic option | 32 |
greece objective | 32 |
vs days | 32 |
significant improvement | 32 |
transplant period | 32 |
time period | 32 |
well established | 32 |
high prevalence | 32 |
metastatic disease | 32 |
cells per | 32 |
solid tumor | 32 |
tumor size | 32 |
neutropenic fever | 32 |
predictive value | 32 |
neoplastic cells | 32 |
human endogenous | 32 |
second line | 32 |
early onset | 32 |
mg ml | 31 |
three times | 31 |
developmental delay | 31 |
better understand | 31 |
age groups | 31 |
second transplant | 31 |
nkt cell | 31 |
reverse transcriptase | 31 |
myeloid cells | 31 |
low igg | 31 |
herpes zoster | 31 |
skin infections | 31 |
blood transfusion | 31 |
humoral immunity | 31 |
cancer survivors | 31 |
obstruction syndrome | 31 |
respiratory syncytial | 31 |
age range | 31 |
kaposi sarcoma | 31 |
colony stimulating | 31 |
complete blood | 31 |
function tests | 31 |
heavy chain | 31 |
human cd | 31 |
pathogenic variants | 31 |
portugal objective | 31 |
mds patients | 31 |
targeted therapy | 31 |
many patients | 31 |
specific cytotoxic | 31 |
respiratory viruses | 31 |
salvage chemotherapy | 31 |
alkaline phosphatase | 31 |
cell adhesion | 31 |
malignant diseases | 31 |
curative therapy | 31 |
twice daily | 31 |
switched memory | 31 |
eligible patients | 31 |
cell membrane | 31 |
apoptotic cells | 31 |
cell carcinomas | 31 |
first day | 31 |
significant morbidity | 31 |
may represent | 30 |
associated herpesvirus | 30 |
red cell | 30 |
antibody levels | 30 |
cell growth | 30 |
microscopic examination | 30 |
patient group | 30 |
acute chest | 30 |
igg mg | 30 |
eleven patients | 30 |
large cell | 30 |
complete resolution | 30 |
staphylococcus aureus | 30 |
refractory acute | 30 |
patients affected | 30 |
adaptive immunity | 30 |
latent infection | 30 |
high frequency | 30 |
better os | 30 |
male patient | 30 |
spindle cells | 30 |
severe aplastic | 30 |
human cytomegalovirus | 30 |
neutralizing antibodies | 30 |
rheumatoid arthritis | 30 |
showed normal | 30 |
small cell | 30 |
response rates | 30 |
trial registry | 30 |
lung tissue | 30 |
animal model | 30 |
expression level | 30 |
years ago | 30 |
intermediate risk | 30 |
cells mcl | 30 |
common cause | 30 |
mouse models | 30 |
binding site | 30 |
reactive protein | 30 |
within normal | 30 |
case highlights | 30 |
patient showed | 30 |
immunodeficiency diseases | 30 |
molecular weight | 30 |
following allogeneic | 30 |
spindle cell | 29 |
laboratory data | 29 |
small number | 29 |
hct recipients | 29 |
therapeutic strategy | 29 |
iga nephropathy | 29 |
steroid refractory | 29 |
affected patients | 29 |
significantly correlated | 29 |
blood transplantation | 29 |
wound healing | 29 |
antibody responses | 29 |
without significant | 29 |
remains unclear | 29 |
nitric oxide | 29 |
chest syndrome | 29 |
primary human | 29 |
clinical findings | 29 |
nucleic acid | 29 |
may result | 29 |
received allo | 29 |
sinusoidal obstruction | 29 |
cells may | 29 |
cell products | 29 |
cell tumors | 29 |
side effect | 29 |
release syndrome | 29 |
gold standard | 29 |
risk acute | 29 |
decision making | 29 |
dna levels | 29 |
laboratory findings | 29 |
humoral immune | 29 |
sample size | 29 |
using flow | 29 |
female patient | 29 |
treatment strategies | 29 |
antiviral activity | 29 |
haemophagocytic syndrome | 29 |
syncytial virus | 29 |
prognostic significance | 29 |
bronchoalveolar lavage | 29 |
allogeneic transplant | 28 |
first report | 28 |
nocturnal enuresis | 28 |
also showed | 28 |
stage ii | 28 |
immune evaluation | 28 |
conventional chemotherapy | 28 |
cd lymphocytes | 28 |
future studies | 28 |
ulcerative colitis | 28 |
wilms tumor | 28 |
antigen processing | 28 |
standard treatment | 28 |
showed significant | 28 |
cd depleted | 28 |
pulmonary fibrosis | 28 |
transgenic mice | 28 |
first patient | 28 |
lung transplantation | 28 |
electronic medical | 28 |
lamina propria | 28 |
ataxia telangiectasia | 28 |
cell survival | 28 |
memory cells | 28 |
severe neutropenia | 28 |
brain tumors | 28 |
gestational age | 28 |
per week | 28 |
pik cd | 28 |
authors declare | 28 |
ebv genome | 28 |
plasma cell | 28 |
normal levels | 28 |
like receptor | 28 |
patients included | 28 |
cell recovery | 28 |
cellular immunity | 28 |
urinary bladder | 28 |
control study | 28 |
alpha beta | 28 |
single centre | 28 |
published data | 28 |
research funding | 28 |
pediatric patient | 28 |
inborn errors | 28 |
better understanding | 28 |
salvage treatment | 28 |
mg daily | 28 |
zu einer | 28 |
term outcomes | 28 |
healthy subjects | 28 |
uncertain significance | 28 |
jazz pharmaceuticals | 28 |
antifungal therapy | 28 |
engraftment occurred | 28 |
blood count | 28 |
proinflammatory cytokines | 28 |
single cell | 27 |
performance status | 27 |
early detection | 27 |
cerebrospinal fluid | 27 |
acute phase | 27 |
infected individuals | 27 |
young adult | 27 |
genes involved | 27 |
cell number | 27 |
mycobacterium tuberculosis | 27 |
like receptors | 27 |
may affect | 27 |
virus associated | 27 |
early post | 27 |
antigen receptor | 27 |
physical exam | 27 |
time point | 27 |
dc leu | 27 |
acute rejection | 27 |
chemotherapy alone | 27 |
adoptive immunotherapy | 27 |
every weeks | 27 |
cell immunity | 27 |
scoring system | 27 |
month old | 27 |
patient cohort | 27 |
often associated | 27 |
still alive | 27 |
determined using | 27 |
stage renal | 27 |
disease severity | 27 |
median survival | 27 |
entire cohort | 27 |
leukemia cells | 27 |
identify patients | 27 |
unknown significance | 27 |
immunohistochemical analysis | 27 |
inflammatory cytokine | 27 |
chemotherapy followed | 27 |
genetic diagnosis | 27 |
blood culture | 27 |
gvhd occurred | 27 |
brain mri | 27 |
related toxicity | 27 |
serum ferritin | 27 |
hek cells | 27 |
recurrent pneumonia | 27 |
kinase inhibitor | 27 |
febrile episodes | 27 |
life threatening | 27 |
will help | 27 |
disease activity | 27 |
heart disease | 27 |
chimeric antigen | 27 |
central venous | 27 |
cyclophosphamide mg | 27 |
related disease | 27 |
increased frequency | 27 |
rank test | 27 |
infectious agents | 27 |
low incidence | 27 |
dna replication | 27 |
preparative regimen | 26 |
study suggests | 26 |
chronic myeloid | 26 |
renal tubular | 26 |
environmental factors | 26 |
medical record | 26 |
dna load | 26 |
event free | 26 |
organ damage | 26 |
stat gof | 26 |
producing cells | 26 |
negative control | 26 |
studies revealed | 26 |
days later | 26 |
central role | 26 |
disease caused | 26 |
node metastasis | 26 |
retrospectively evaluated | 26 |
year cumulative | 26 |
different types | 26 |
van het | 26 |
gata deficiency | 26 |
autologous transplantation | 26 |
homozygous mutation | 26 |
surgical excision | 26 |
nucleated cells | 26 |
tumour cells | 26 |
limited data | 26 |
blood vessels | 26 |
several studies | 26 |
study shows | 26 |
kidney transplantation | 26 |
normal controls | 26 |
university medical | 26 |
post hct | 26 |
twelve patients | 26 |
liver function | 26 |
intensive chemotherapy | 26 |
hla identical | 26 |
cell replete | 26 |
regression model | 26 |
old caucasian | 26 |
cd dose | 26 |
reported cases | 26 |
haploidentical hematopoietic | 26 |
causative agent | 26 |
children undergoing | 26 |
patients responded | 26 |
cells infected | 26 |
lymphocytic leukemia | 26 |
dna binding | 26 |
early childhood | 26 |
risk stratification | 26 |
salivary gland | 26 |
therapeutic strategies | 26 |
natural history | 26 |
lymphoblastoid cell | 26 |
infused cd | 26 |
hospital stay | 26 |
beam group | 26 |
allogeneic haematopoietic | 26 |
growth factors | 26 |
literature review | 26 |
female ratio | 26 |
advanced disease | 26 |
per kg | 26 |
immunosuppressive drugs | 26 |
allogeneic bone | 25 |
reactive oxygen | 25 |
donor age | 25 |
dose steroids | 25 |
preemptive therapy | 25 |
may cause | 25 |
higher rate | 25 |
unrelated cord | 25 |
chronic renal | 25 |
negative patients | 25 |
results obtained | 25 |
western blotting | 25 |
specific igg | 25 |
data demonstrate | 25 |
pulmonary disease | 25 |
spectrum antibiotics | 25 |
post asct | 25 |
alternative donor | 25 |
promising results | 25 |
oxygen species | 25 |
poorly understood | 25 |
parenteral nutrition | 25 |
primary endpoint | 25 |
cardiovascular disease | 25 |
paraffin embedded | 25 |
posttransplant lymphoproliferative | 25 |
cell repertoire | 25 |
treatment failure | 25 |
severe gvhd | 25 |
large cohort | 25 |
analyzed patients | 25 |
intestinal gvhd | 25 |
model group | 25 |
highly conserved | 25 |
blood counts | 25 |
without evidence | 25 |
steroid therapy | 25 |
wide range | 25 |
new york | 25 |
urothelial carcinoma | 25 |
multicenter study | 25 |
assessed using | 25 |
patient experienced | 25 |
mean number | 25 |
lung biopsy | 25 |
fold increase | 25 |
igg positive | 25 |
plasmodium falciparum | 25 |
cd ratio | 25 |
granulocyte colony | 25 |
healthy donor | 25 |
clinical signs | 25 |
primary tumor | 25 |
rare case | 25 |
phase ii | 25 |
interferon gamma | 25 |
mean time | 25 |
gastric cancer | 25 |
somatic mutations | 25 |
receptor excision | 25 |
viral proteins | 25 |
three years | 25 |
new therapeutic | 25 |
female presented | 25 |
treatment modality | 25 |
less likely | 25 |
calculated using | 25 |
control groups | 25 |
immunohistochemical expression | 25 |
left ventricular | 25 |
donor source | 25 |
hazard ratio | 25 |
exact test | 25 |
post transplantation | 25 |
skin biopsy | 25 |
identified patients | 24 |
days vs | 24 |
possible role | 24 |
prrs outbreak | 24 |
patients years | 24 |
cytokine levels | 24 |
therapeutic options | 24 |
advanced stage | 24 |
protein kinase | 24 |
inhibitory effect | 24 |
high rates | 24 |
also significantly | 24 |
immunosuppressive agents | 24 |
chronic lung | 24 |
binding protein | 24 |
synovial sarcoma | 24 |
viral hepatitis | 24 |
observational study | 24 |
bis zu | 24 |
body mass | 24 |
type diabetes | 24 |
steroid treatment | 24 |
healthy children | 24 |
cellular immune | 24 |
chronic inflammatory | 24 |
small molecule | 24 |
paediatric patients | 24 |
czech republic | 24 |
host cells | 24 |
invasive aspergillosis | 24 |
evans syndrome | 24 |
showed significantly | 24 |
acute renal | 24 |
blood donors | 24 |
comorbidity index | 24 |
ae ae | 24 |
transplant complications | 24 |
ct scans | 24 |
prophylactic antibiotics | 24 |
birth weight | 24 |
fusion protein | 24 |
combination therapy | 24 |
mri showed | 24 |
revealed normal | 24 |
genetic evaluation | 24 |
cell compartment | 24 |
rag deficiency | 24 |
groups according | 24 |
cancer center | 24 |
induced apoptosis | 24 |
haematological malignancies | 24 |
lymphoproliferative syndrome | 24 |
vascular malformations | 24 |
heterogeneous group | 24 |
hematopoietic cells | 24 |
cell subset | 24 |
descriptive statistics | 24 |
adhesion molecules | 24 |
clinical studies | 24 |
patients met | 24 |
better survival | 24 |
studies suggest | 24 |
peripheral stem | 24 |
lymphoma cells | 24 |
myeloid malignancies | 24 |
colon cancer | 24 |
lower incidence | 24 |
western blots | 24 |
respiratory symptoms | 24 |
hies patients | 24 |
young patients | 24 |
mantle cell | 23 |
similar results | 23 |
fully matched | 23 |
specific immune | 23 |
severe sepsis | 23 |
node biopsy | 23 |
platelet transfusions | 23 |
relapse free | 23 |
inflammatory responses | 23 |
streptococcus pneumoniae | 23 |
brazil objective | 23 |
relapsed disease | 23 |
hsct using | 23 |
previously published | 23 |
independent prognostic | 23 |
ko mice | 23 |
data regarding | 23 |
based regimen | 23 |
severe disease | 23 |
dominant negative | 23 |
leukemic cells | 23 |
kommt es | 23 |
clinical parameters | 23 |
targeted therapies | 23 |
portal hypertension | 23 |
average number | 23 |
average time | 23 |
lower risk | 23 |
functional studies | 23 |
already published | 23 |
thyroid carcinoma | 23 |
salivary glands | 23 |
family donors | 23 |
longer follow | 23 |
cik cells | 23 |
immune globulin | 23 |
improved survival | 23 |
baseline characteristics | 23 |
genetic correlation | 23 |
donor cells | 23 |
latently infected | 23 |
gene mutations | 23 |
relapsed aml | 23 |
malignant cells | 23 |
median interval | 23 |
organ dysfunction | 23 |
single dose | 23 |
th cytokines | 23 |
cancer therapy | 23 |
male presented | 23 |
differentially expressed | 23 |
spain objective | 23 |
clinical significance | 23 |
dna polymerase | 23 |
renal impairment | 23 |
patients will | 23 |
positively correlated | 23 |
first reported | 23 |
overall mortality | 23 |
lung transplant | 23 |
abstract already | 23 |
serious adverse | 23 |
marginal zone | 23 |
refractory agvhd | 23 |
tumor suppressor | 23 |
independently associated | 23 |
evaluation revealed | 23 |
stat phosphorylation | 23 |
viral genome | 23 |
patients reported | 23 |
significantly elevated | 23 |
endogenous retrovirus | 23 |
clinical management | 23 |
icu mortality | 23 |
viral antigens | 23 |
conditioning therapy | 23 |
poor mobilizers | 23 |
gi tract | 23 |
scan showed | 23 |
clinical background | 23 |
ecp treatment | 23 |
mitotic activity | 23 |
first complete | 23 |
antibody production | 22 |
reduced toxicity | 22 |
different clinical | 22 |
ige syndrome | 22 |
high morbidity | 22 |
pediatric hsct | 22 |
human genome | 22 |
plasma samples | 22 |
common complication | 22 |
nucleic acids | 22 |
russia objective | 22 |
cumulative incidences | 22 |
molecular basis | 22 |
measles virus | 22 |
undergoing allo | 22 |
linear regression | 22 |
received chemotherapy | 22 |
mass spectrometry | 22 |
meier method | 22 |
virus reactivation | 22 |
cells within | 22 |
antigen specific | 22 |
mutation analysis | 22 |
biopsy specimens | 22 |
trough levels | 22 |
study aims | 22 |
neutralizing activity | 22 |
cells ml | 22 |
patients following | 22 |
actin cytoskeleton | 22 |
th day | 22 |
autoimmune disorders | 22 |
tlr ligands | 22 |
germinal center | 22 |
cells expressed | 22 |
clinical presentations | 22 |
allogenic hematopoietic | 22 |
compared using | 22 |
primary tumors | 22 |
higher expression | 22 |
mass index | 22 |
disease burden | 22 |
previously shown | 22 |
disease onset | 22 |
cell lung | 22 |
large number | 22 |
clear cell | 22 |
immune recovery | 22 |
novel mutation | 22 |
cytomegalovirus infection | 22 |
vast majority | 22 |
ric regimen | 22 |
igg antibodies | 22 |
evaluable patients | 22 |
initial evaluation | 22 |
laboratory evaluation | 22 |
gene products | 22 |
graft survival | 22 |
severe complication | 22 |
cell collection | 22 |
short stature | 22 |
cell tumor | 22 |
chronic lymphocytic | 22 |
tumor progression | 22 |
cells using | 22 |
studies show | 22 |
initially presented | 22 |
genetic defect | 22 |
years later | 22 |
infected mice | 22 |
urinary protein | 22 |
antibiotic treatment | 22 |
pain control | 22 |
poor graft | 22 |
cd monoclonal | 22 |
cmv dna | 22 |
histopathological examination | 21 |
complement activation | 21 |
allograft recipients | 21 |
public health | 21 |
brentuximab vedotin | 21 |
iv antibiotics | 21 |
conditioned patients | 21 |
graft vs | 21 |
inflammatory diseases | 21 |
median overall | 21 |
frequently used | 21 |
germany objective | 21 |
epstein barr | 21 |
cell maturation | 21 |
cell infusion | 21 |
functional assays | 21 |
abstract withdrawn | 21 |
virus dna | 21 |
human peripheral | 21 |
data collection | 21 |
testing revealed | 21 |
transplant outcome | 21 |
data collected | 21 |
newborn screen | 21 |
sectional study | 21 |
treatment modalities | 21 |
absolute lymphocyte | 21 |
nutritional status | 21 |
linked cgd | 21 |
splice site | 21 |
disorder characterized | 21 |
showed diffuse | 21 |
cd antibody | 21 |
primary disease | 21 |
high expression | 21 |
pilot study | 21 |
second patient | 21 |
showed high | 21 |
cardiac surgery | 21 |
times per | 21 |
serum immunoglobulin | 21 |
early relapse | 21 |
iron deficiency | 21 |
histological features | 21 |
multivariable analysis | 21 |
immune activation | 21 |
severe thrombocytopenia | 21 |
threatening complication | 21 |
first dose | 21 |
lung function | 21 |
cell immune | 21 |
influenza viruses | 21 |
mrd group | 21 |
breast carcinomas | 21 |
major role | 21 |
iii iv | 21 |
csf group | 21 |
low level | 21 |
likely pathogenic | 21 |
higher cd | 21 |
expression profile | 21 |
differential expression | 21 |
distress syndrome | 21 |
serum level | 21 |
breast milk | 21 |
kidney transplant | 21 |
children treated | 21 |
higher rates | 21 |
pediatric renal | 21 |
single agent | 21 |
remission status | 21 |
risk cytogenetics | 21 |
month post | 21 |
transplant centers | 21 |
thymic epithelial | 21 |
serious complication | 21 |
blot analysis | 21 |
agvhd patients | 21 |
antibiotic prophylaxis | 21 |
type ii | 21 |
stranded rna | 21 |
least months | 21 |
extracellular matrix | 21 |
dose melphalan | 21 |
cells compared | 21 |
mhc i | 21 |
showed severe | 21 |
marrow aspirate | 21 |
rna interference | 21 |
gi agvhd | 21 |
mutant mice | 21 |
cell expansion | 21 |
early death | 21 |
prognostic value | 21 |
respiratory virus | 21 |
male female | 21 |
year follow | 21 |
disease risk | 21 |
pediatric nephrology | 21 |
single institution | 21 |
total cd | 21 |
negative selection | 21 |
therapeutic targets | 21 |
previous reports | 21 |
early mortality | 21 |
first years | 21 |
national university | 21 |
lower gi | 21 |
received allogeneic | 21 |
selected patients | 21 |
kg bw | 21 |
human leukocyte | 21 |
healthy volunteers | 21 |
reported case | 20 |
high index | 20 |
pts died | 20 |
absolute number | 20 |
engraftment failure | 20 |
clinical phenotypes | 20 |
cd depletion | 20 |
case description | 20 |
thrombocytopenic purpura | 20 |
received rituximab | 20 |
laboratory studies | 20 |
clinical study | 20 |
post allo | 20 |
cells obtained | 20 |
gastric carcinoma | 20 |
good response | 20 |
mutational status | 20 |
cytokine secretion | 20 |
young age | 20 |
peritoneal dialysis | 20 |
closely related | 20 |
patients submitted | 20 |
treg cells | 20 |
complete donor | 20 |
heart transplant | 20 |
treatment response | 20 |
center study | 20 |
cytogenetic risk | 20 |
statistically different | 20 |
medical sciences | 20 |
mobilized peripheral | 20 |
renal involvement | 20 |
chronic inflammation | 20 |
met een | 20 |
cells transplantation | 20 |
type mice | 20 |
mechanisms underlying | 20 |
lower levels | 20 |
hematopoetic stem | 20 |
sixteen patients | 20 |
likely due | 20 |
patients presenting | 20 |
high resolution | 20 |
sle patients | 20 |
data suggests | 20 |
better outcome | 20 |
disease course | 20 |
transplant characteristics | 20 |
four years | 20 |
lymphoid cells | 20 |
papillary thyroid | 20 |
porcine reproductive | 20 |
cell transplants | 20 |
avian influenza | 20 |
past medical | 20 |
statistical difference | 20 |
ill patients | 20 |
mononuclear cell | 20 |
bl mice | 20 |
intraepithelial neoplasia | 20 |
corticosteroid therapy | 20 |
patients admitted | 20 |
chronic diarrhea | 20 |
adverse reactions | 20 |
bal samples | 20 |
early stages | 20 |
initial diagnosis | 20 |
two days | 20 |
therapeutic approach | 20 |
cox proportional | 20 |
remained stable | 20 |
immunodeficiency disease | 20 |
cell lysates | 20 |
china objective | 20 |
viral particles | 20 |
gastrointestinal symptoms | 20 |
recent study | 20 |
mrd negative | 20 |
north america | 20 |
relapse risk | 20 |
heart failure | 20 |
cystic fibrosis | 20 |
based regimens | 20 |
nonrelapse mortality | 20 |
systemic treatment | 20 |
evaluation showed | 20 |
iran objective | 20 |
drug interactions | 20 |
elevated ige | 20 |
antimicrobial therapy | 20 |
target genes | 20 |
one episode | 20 |
related infections | 20 |
gata mutation | 20 |
cell cultures | 20 |
von willebrand | 20 |
independent risk | 20 |
end point | 20 |
immunohistochemical study | 20 |
lof stat | 20 |
based gvhd | 20 |
dengue virus | 20 |
three pts | 20 |
arterial hypertension | 20 |
absolute cd | 20 |
scd patients | 20 |
gene amplification | 20 |
group vs | 20 |
patient samples | 20 |
risk disease | 20 |
immune status | 20 |
syndrome virus | 20 |
study demonstrates | 20 |
romania objective | 20 |
clinical history | 20 |
except one | 20 |
remains controversial | 20 |
malignant transformation | 20 |
adverse event | 20 |
increased incidence | 20 |
patients also | 20 |
gene encoding | 20 |
data obtained | 20 |
ebv pcr | 20 |
elevated levels | 20 |
regulatory cells | 20 |
cell mediated | 20 |
cd car | 19 |
linked agammaglobulinemia | 19 |
pathogenic mutation | 19 |
induction treatment | 19 |
factor receptor | 19 |
cancer diagnosis | 19 |
aspergillus fumigatus | 19 |
patients develop | 19 |
heterozygous missense | 19 |
cases showed | 19 |
described previously | 19 |
fourteen patients | 19 |
enzyme replacement | 19 |
also performed | 19 |
kg per | 19 |
acid levels | 19 |
acute infection | 19 |
tumor grade | 19 |
among individuals | 19 |
ferritin levels | 19 |
may serve | 19 |
graft loss | 19 |
short course | 19 |
receptor expression | 19 |
lymphocyte subpopulations | 19 |
alive without | 19 |
severe anemia | 19 |
mycobacterial infections | 19 |
clinically relevant | 19 |
autologous hct | 19 |
cd foxp | 19 |
kinase inhibitors | 19 |
connective tissue | 19 |
immune function | 19 |
hsct setting | 19 |
het virus | 19 |
inflammatory cells | 19 |
cellular therapy | 19 |
treatment strategy | 19 |
ebv viral | 19 |
vaccinia virus | 19 |
absolute counts | 19 |
potential role | 19 |
immunodeficiency syndrome | 19 |
risk neuroblastoma | 19 |
phase study | 19 |
transgene expression | 19 |
plerixafor group | 19 |
ebv transformation | 19 |
lymphocyte subset | 19 |
quality control | 19 |
proteins involved | 19 |
cell sources | 19 |
cell epitopes | 19 |
survival analysis | 19 |
well documented | 19 |
mud mmud | 19 |
vitro studies | 19 |
effective therapy | 19 |
report two | 19 |
worse prognosis | 19 |
children aged | 19 |
cd levels | 19 |
may benefit | 19 |
recombinant human | 19 |
immune tolerance | 19 |
recurrent bacterial | 19 |
relapse rates | 19 |
five cases | 19 |
complete chimerism | 19 |
cases reported | 19 |
risk aml | 19 |
specific treatment | 19 |
patients using | 19 |
weeks later | 19 |
developed cmv | 19 |
familial hemophagocytic | 19 |
patient care | 19 |
full length | 19 |
enrolled patients | 19 |
definitive diagnosis | 19 |
results support | 19 |
received dli | 19 |
needle biopsy | 19 |
gvhd patients | 19 |
old patient | 19 |
risk features | 19 |
also reported | 19 |
every months | 19 |
primary cutaneous | 19 |
cells play | 19 |
genetic alterations | 19 |
well described | 19 |
four cases | 19 |
frequently associated | 19 |
central memory | 19 |
donor cell | 19 |
mainly due | 19 |
total rna | 19 |
specific anti | 19 |
novel therapeutic | 19 |
life cycle | 19 |
blood transplant | 19 |
lentiviral vector | 19 |
autoimmune lymphoproliferative | 19 |
elevated liver | 19 |
commercially available | 19 |
primary ebv | 19 |
unknown origin | 19 |
bronchiolitis obliterans | 19 |
research center | 19 |
antibody deficiencies | 19 |
blood volume | 19 |
patient groups | 19 |
hematological recovery | 19 |
higher frequency | 19 |
seasonal influenza | 19 |
severe complications | 19 |
health status | 19 |
reference range | 19 |
may improve | 19 |
active infection | 19 |
blood flow | 19 |
done using | 19 |
tertiary care | 19 |
host defense | 18 |
human herpes | 18 |
data support | 18 |
ada deficiency | 18 |
revealed low | 18 |
crispr cas | 18 |
red cross | 18 |
immune evasion | 18 |
relatively low | 18 |
serum immunoglobulins | 18 |
immunodeficiency disorders | 18 |
viral mirnas | 18 |
phox cgd | 18 |
ebv transformed | 18 |
phage library | 18 |
months old | 18 |
pediatric transplant | 18 |
primary outcome | 18 |
cd counts | 18 |
fanconi anemia | 18 |
post sct | 18 |
cells express | 18 |
laboratory parameters | 18 |
mediated immunity | 18 |
cell sorting | 18 |
rna sequencing | 18 |
stat mutations | 18 |
dna methylation | 18 |
may explain | 18 |
caucasian male | 18 |
pts receiving | 18 |
following hematopoietic | 18 |
chronic infection | 18 |
ccr expression | 18 |
gi gvhd | 18 |
mrna levels | 18 |
investigate whether | 18 |
alternative donors | 18 |
evaluated using | 18 |
multivariate analyses | 18 |
apoptotic cell | 18 |
function mutation | 18 |
mg twice | 18 |
rare autosomal | 18 |
double negative | 18 |
underwent haplo | 18 |
endothelial cell | 18 |
allergy immunology | 18 |
pneumocystis jirovecii | 18 |
recently described | 18 |
cases diagnosed | 18 |
developed agvhd | 18 |
day survival | 18 |
first described | 18 |
log rank | 18 |
node metastases | 18 |
skin rash | 18 |
respiratory infection | 18 |
sh domain | 18 |
significant changes | 18 |
liver toxicity | 18 |
emergency department | 18 |
allogenic hsct | 18 |
index patient | 18 |
randomly selected | 18 |
therapeutic target | 18 |
ra cd | 18 |
study provides | 18 |
also included | 18 |
inflammatory markers | 18 |
also detected | 18 |
virus latent | 18 |
tissue microarray | 18 |
heavily pretreated | 18 |
consanguineous parents | 18 |
hospital universitario | 18 |
excision circles | 18 |
clinical picture | 18 |
standard therapy | 18 |
years overall | 18 |
four weeks | 18 |
early recognition | 18 |
liposomal amphotericin | 18 |
candida albicans | 18 |
pediatric intensive | 18 |
human papillomavirus | 18 |
multiorgan failure | 18 |
malignant tumors | 18 |
donor lymphocytes | 18 |
chemotherapeutic agents | 18 |
using elisa | 18 |
surviving patients | 18 |
raji cells | 18 |
previously treated | 18 |
rare complication | 18 |
mice showed | 18 |
twenty patients | 18 |
rare tumor | 18 |
frequent complication | 18 |
risk groups | 18 |
molecular analysis | 18 |
collected data | 18 |
pleural effusion | 18 |
ebv viremia | 18 |
highly active | 18 |
normal control | 18 |
time quantitative | 18 |
calcineurin inhibitor | 18 |
kg body | 18 |
norm model | 18 |
also received | 18 |
axillary lymph | 18 |
adv infection | 18 |
total dose | 18 |
patients whose | 18 |
transfected cells | 18 |
mental status | 18 |
renal injury | 18 |
also present | 18 |
younger age | 18 |
flow cytometer | 18 |
platelet aggregation | 18 |
treated mice | 18 |
additional patients | 18 |
may influence | 18 |
room temperature | 18 |
hospital medical | 18 |
oncology group | 18 |
congenital heart | 18 |
recurrent skin | 18 |
higher number | 18 |
data analysis | 18 |
adhesion molecule | 18 |
immunological synapse | 18 |
trec levels | 18 |
risk score | 18 |
institutional review | 18 |
activation syndrome | 18 |
relatively high | 18 |
malignant melanoma | 18 |
threatening complications | 18 |
endogenous retroviruses | 18 |
systematic review | 18 |
several years | 18 |
prognostic impact | 18 |
largely unknown | 18 |
protein level | 17 |
remains unknown | 17 |
least two | 17 |
patients suffered | 17 |
different stages | 17 |
correlation coefficient | 17 |
donor transplant | 17 |
cell cytotoxicity | 17 |
received peripheral | 17 |
cervical lymphadenopathy | 17 |
close monitoring | 17 |
times daily | 17 |
culture system | 17 |
os rates | 17 |
cancer treatment | 17 |
cell transplantations | 17 |
elevated igg | 17 |
low iga | 17 |
recessive disorder | 17 |
subsequently developed | 17 |
posttransplant cyclophosphamide | 17 |
fusion proteins | 17 |
showed complete | 17 |
italy objective | 17 |
world health | 17 |
treatment groups | 17 |
pivotal role | 17 |
first two | 17 |
steady state | 17 |
second hsct | 17 |
lower extremity | 17 |
myeloid leukaemia | 17 |
four months | 17 |
immunologic evaluation | 17 |
patients present | 17 |
haploidentical family | 17 |
ige levels | 17 |
pulmonary infection | 17 |
effector functions | 17 |
myelomonocytic leukemia | 17 |
transplant candidates | 17 |
whereas patients | 17 |
cytomegalovirus reactivation | 17 |
larger cohort | 17 |
mechanisms involved | 17 |
acquired immunodeficiency | 17 |
refractory gvhd | 17 |
transplantation cyclophosphamide | 17 |
adenovirus infection | 17 |
infection associated | 17 |
invasive breast | 17 |
limited number | 17 |
beta thalassemia | 17 |
increased significantly | 17 |
reactivation occurred | 17 |
major complication | 17 |
significant proportion | 17 |
light microscopy | 17 |
sequence analysis | 17 |
oral mucositis | 17 |
germ cell | 17 |
retrospectively analysed | 17 |
strongly associated | 17 |
neutropenic patients | 17 |
recently identified | 17 |
live vaccines | 17 |
cytokine response | 17 |
host cell | 17 |
helper cells | 17 |
wbc count | 17 |
vascular endothelial | 17 |
kir dl | 17 |
complex karyotype | 17 |
highly expressed | 17 |
classified according | 17 |
ductal carcinoma | 17 |
unmanipulated haploidentical | 17 |
activated cd | 17 |
term survivors | 17 |
protective immunity | 17 |
signet ring | 17 |
growth hormone | 17 |
tumor development | 17 |
molecular diagnosis | 17 |
fold higher | 17 |
glomerular filtration | 17 |
hodgkin lymphomas | 17 |
cell clones | 17 |
poor outcomes | 17 |
therapy may | 17 |
without gvhd | 17 |
die diagnose | 17 |
gene rearrangement | 17 |
ctla ig | 17 |
extracellular vesicles | 17 |
positive plasma | 17 |
antiviral agents | 17 |
sore throat | 17 |
cd memory | 17 |
mcg kg | 17 |
morpholino oligomers | 17 |
patient survival | 17 |
negative bacteria | 17 |
blood cd | 17 |
past years | 17 |
two children | 17 |
aml mds | 17 |
allo hsct | 17 |
multivariate cox | 17 |
autoimmune manifestations | 17 |
antiviral drugs | 17 |
recurrent episodes | 17 |
ec ii | 17 |
surgical specimens | 17 |
low doses | 17 |
hematological diseases | 17 |
considered statistically | 17 |
lipid rafts | 17 |
intracellular cytokine | 17 |
cancer institute | 17 |
mortality rates | 17 |
year later | 17 |
lytic cycle | 17 |
dose therapy | 17 |
located within | 17 |
nadph oxidase | 17 |
ebv infectivity | 17 |
good partial | 17 |
well circumscribed | 17 |
two pts | 17 |
clinical manifestation | 17 |
globin gene | 17 |
cell grafts | 17 |
carcinoma cells | 17 |
novel agents | 17 |
investigated whether | 17 |
igm levels | 17 |
infection may | 17 |
gvhd incidence | 17 |
phage display | 17 |
lymphoid organs | 17 |
three different | 17 |
confocal microscopy | 17 |
sct group | 17 |
increased levels | 17 |
autologous peripheral | 17 |
quantitative real | 17 |
irb approval | 17 |
systemic steroids | 17 |
positive blood | 17 |
surface markers | 17 |
serum albumin | 17 |
received bone | 17 |
cytotoxic activity | 17 |
donor hsct | 17 |
net state | 17 |
two cohorts | 17 |
using standard | 16 |
group received | 16 |
blood transfusions | 16 |
month period | 16 |
different cell | 16 |
hla antibodies | 16 |
binding domain | 16 |
hsct performed | 16 |
activation markers | 16 |
developing countries | 16 |
copy numbers | 16 |
responded well | 16 |
igm mg | 16 |
treatment regimens | 16 |
laboratory tests | 16 |
using spss | 16 |
cells stimulated | 16 |
cells also | 16 |
dna damage | 16 |
early stage | 16 |
gram negative | 16 |
philadelphia chromosome | 16 |
day mortality | 16 |
hla typing | 16 |
myelodysplastic syndromes | 16 |
survivin expression | 16 |
major severe | 16 |
high doses | 16 |
six weeks | 16 |
embedded tissue | 16 |
ctla haploinsufficiency | 16 |
prophylaxis regimens | 16 |
vgamma vdelta | 16 |
frequently observed | 16 |
small bowel | 16 |
dose cyclophosphamide | 16 |
positive cases | 16 |
organ toxicity | 16 |
one day | 16 |
complement pathway | 16 |
financial support | 16 |
days prior | 16 |
larger studies | 16 |
fas ligand | 16 |
fully understood | 16 |
regression models | 16 |
cell histiocytosis | 16 |
pidd patients | 16 |
small sample | 16 |
grade vur | 16 |
haploidentical transplants | 16 |
bei kindern | 16 |
last decade | 16 |
lymphocytic interstitial | 16 |
mean value | 16 |
square test | 16 |
phase iii | 16 |
normal limits | 16 |
segmental glomerulosclerosis | 16 |
growth pattern | 16 |
platelet transfusion | 16 |
based therapy | 16 |
leukocyte antigen | 16 |
brain injury | 16 |
genetic defects | 16 |
cytokine profile | 16 |
late onset | 16 |
useful tool | 16 |
hematology department | 16 |
immediate early | 16 |
toxicity profile | 16 |
oral cavity | 16 |
treatment lines | 16 |
vaccine responses | 16 |
histological type | 16 |
syndrome associated | 16 |
primary refractory | 16 |
consecutive adult | 16 |
three weeks | 16 |
may reflect | 16 |
like phenotype | 16 |
one child | 16 |
otherwise healthy | 16 |
wt mice | 16 |
showed increased | 16 |
matched healthy | 16 |
rabbit atg | 16 |
related toxicities | 16 |
clostridium difficile | 16 |
lytic replication | 16 |
cd neg | 16 |
langerhans cell | 16 |
acute otitis | 16 |
cik cell | 16 |
celiac disease | 16 |
reproductive performance | 16 |
systemic inflammation | 16 |
inhibitory effects | 16 |
frequent cause | 16 |
histological grade | 16 |
effector function | 16 |
cell activity | 16 |
early phase | 16 |
one died | 16 |
cytometric analysis | 16 |
quantitative analysis | 16 |
potential risk | 16 |
dilating vur | 16 |
metastatic potential | 16 |
human disease | 16 |
survival outcomes | 16 |
clinimacs prodigy | 16 |
distant metastases | 16 |
hematopoietic recovery | 16 |
derived dendritic | 16 |
treated cells | 16 |
health organization | 16 |
igg trough | 16 |
respiratory viral | 16 |
odds ratio | 16 |
patient also | 16 |
thirteen patients | 16 |
cells transfected | 16 |
also associated | 16 |
longer time | 16 |
ml kg | 16 |
diagnostic tool | 16 |
severe hemophilia | 16 |
received mg | 16 |
clinical research | 16 |
single nucleotide | 16 |
chest ct | 16 |
review board | 16 |
sequential conditioning | 16 |
posttransplant period | 16 |
systemic disease | 16 |
less severe | 16 |
luciferase reporter | 16 |
results confirm | 16 |
surgical treatment | 16 |
csa treatment | 16 |
patients characteristics | 16 |
effective therapeutic | 16 |
case study | 16 |
also analyzed | 16 |
extremely low | 16 |
bleeding episodes | 16 |
childrens hospital | 16 |
systemic corticosteroids | 16 |
health outcomes | 16 |
influenza vaccine | 16 |
marrow derived | 16 |
allowed us | 16 |
exclusion criteria | 16 |
disease associated | 16 |
analysis using | 16 |
group showed | 16 |
fluid overload | 16 |
improve outcomes | 16 |
low rates | 16 |
antimicrobial agents | 16 |
recipient cells | 16 |
specific ctl | 16 |
mice compared | 16 |
synovial sarcomas | 16 |
imaging showed | 16 |
pbsc grafts | 16 |
plasma exchange | 16 |
included children | 16 |
using anti | 16 |
international prognostic | 16 |
infection risk | 16 |
recipient weight | 16 |
immunology clinic | 16 |
depleted haploidentical | 16 |
patients remain | 16 |
high serum | 16 |
unclear whether | 16 |
first hours | 16 |
lower extremities | 16 |
received either | 16 |
retrospectively collected | 16 |
enzymatic activity | 16 |
hematologic diseases | 16 |
myelogenous leukemia | 16 |
month follow | 16 |
donor recipient | 16 |
risk mds | 16 |
physical functioning | 16 |
one third | 16 |
medical faculty | 16 |
including patients | 16 |
facs analysis | 16 |
negative impact | 16 |
transplantation unit | 16 |
oxidative burst | 16 |
interstitial fibrosis | 16 |
initially treated | 16 |
cell transformation | 16 |
cell doses | 16 |
previously unreported | 16 |
oral ulcers | 16 |
pseudomonas aeruginosa | 16 |
significantly shorter | 15 |
severe congenital | 15 |
without agvhd | 15 |
ecp procedures | 15 |
disease manifestations | 15 |
pleural effusions | 15 |
ucsf benioff | 15 |
two doses | 15 |
six cases | 15 |
negative correlation | 15 |
recombinant factor | 15 |
formalin fixed | 15 |
genetic disorder | 15 |
retrospectively studied | 15 |
classical hodgkin | 15 |
may require | 15 |
idiopathic pulmonary | 15 |
helicobacter pylori | 15 |
skin abscesses | 15 |
commonly associated | 15 |
schonlein purpura | 15 |
gastrointestinal stromal | 15 |
severe infection | 15 |
strong correlation | 15 |
several months | 15 |
induction regimens | 15 |
urine ngal | 15 |
nhl patients | 15 |
also seen | 15 |
renal insufficiency | 15 |
immune escape | 15 |
allogenic stem | 15 |
duffy null | 15 |
thyroid cancer | 15 |
ui ml | 15 |
physical therapy | 15 |
prospective trials | 15 |